Another preclinical study showed that whole-tumor vaccines producing granulocyte macrophage colony-stimulating factor (GM-CSF) greatly enhanced anti-CTLA-4 blockade efficacy against pancreatic and prostate cancers. The gene discussed is CTLA4; the disease is prostate cancer.